Cost-Effectiveness of Ipilimumab Plus Anti-PD-1 Therapy Versus Ipilimumab Alone in Patients With Metastatic Melanoma Resistant to Anti-PD-(L)1 Monotherapy

ObjectiveThe use of ipilimumab plus anti-PD-1 has recently been shown to significantly improve the survival of patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy. The study assessed the cost-effectiveness of ipilimumab plus anti-PD-1 therapy in this population from the US payer...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ye Peng, Xiaohui Zeng, Liubao Peng, Qiao Liu, Lidan Yi, Xia Luo, Sini Li, Liting Wang, Shuxia Qin, Xiaomin Wan, Chongqing Tan
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	ipilimumab plus anti-PD-1 retrospective analysis cost-effectiveness melanoma Markov model Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/a2d7426549cb4e0a9fd8038f8f4f447a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a2d7426549cb4e0a9fd8038f8f4f447a
record_format	dspace
spelling	oai:doaj.org-article:a2d7426549cb4e0a9fd8038f8f4f447a2021-11-09T06:31:49ZCost-Effectiveness of Ipilimumab Plus Anti-PD-1 Therapy Versus Ipilimumab Alone in Patients With Metastatic Melanoma Resistant to Anti-PD-(L)1 Monotherapy2234-943X10.3389/fonc.2021.743765https://doaj.org/article/a2d7426549cb4e0a9fd8038f8f4f447a2021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fonc.2021.743765/fullhttps://doaj.org/toc/2234-943XObjectiveThe use of ipilimumab plus anti-PD-1 has recently been shown to significantly improve the survival of patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy. The study assessed the cost-effectiveness of ipilimumab plus anti-PD-1 therapy in this population from the US payer perspective.Materials and MethodsA Markov model was created based on a retrospective analysis of patients with metastatic melanoma who were resistant to anti-PD-(L)1. Cost information was obtained from the Centers for Medicare and Medicaid Services and literature-based costs. The utility value was derived from the published literature. The results of the model was the total cost, quality-adjusted life-year (QALY), and incremental cost-effectiveness ratio (ICER). The uncertainty of the model was addressed through sensitivity analysis. In addition, we also conducted subgroup analysis.ResultsIpilimumab plus anti-PD-1 provided an improvement of 1.39 QALYs and 2.48 LYs, at a ICER of $73,163 per QALY. The HR of OS was the variable that had the greatest impact on ICER. Compared to ipilimumab, the probability of ipilimumab plus anti-PD-1 being cost-effective was 94% at the WTP of $150,000/QALY. The results of the subgroup analysis showed that the ICER in the majority of the subgroups was less than $150,000/QALY.ConclusionsIpilimumab plus anti-PD-1 was likely to be cost-effective compared to ipilimumab for patients with metastatic melanoma who are resistant to anti-PD-(L)1 at a WTP threshold of 150,000/QALY.Ye PengXiaohui ZengLiubao PengQiao LiuLidan YiXia LuoSini LiLiting WangShuxia QinXiaomin WanChongqing TanFrontiers Media S.A.articleipilimumab plus anti-PD-1retrospective analysiscost-effectivenessmelanomaMarkov modelNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENFrontiers in Oncology, Vol 11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	ipilimumab plus anti-PD-1 retrospective analysis cost-effectiveness melanoma Markov model Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	ipilimumab plus anti-PD-1 retrospective analysis cost-effectiveness melanoma Markov model Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Ye Peng Xiaohui Zeng Liubao Peng Qiao Liu Lidan Yi Xia Luo Sini Li Liting Wang Shuxia Qin Xiaomin Wan Chongqing Tan Cost-Effectiveness of Ipilimumab Plus Anti-PD-1 Therapy Versus Ipilimumab Alone in Patients With Metastatic Melanoma Resistant to Anti-PD-(L)1 Monotherapy
description	ObjectiveThe use of ipilimumab plus anti-PD-1 has recently been shown to significantly improve the survival of patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy. The study assessed the cost-effectiveness of ipilimumab plus anti-PD-1 therapy in this population from the US payer perspective.Materials and MethodsA Markov model was created based on a retrospective analysis of patients with metastatic melanoma who were resistant to anti-PD-(L)1. Cost information was obtained from the Centers for Medicare and Medicaid Services and literature-based costs. The utility value was derived from the published literature. The results of the model was the total cost, quality-adjusted life-year (QALY), and incremental cost-effectiveness ratio (ICER). The uncertainty of the model was addressed through sensitivity analysis. In addition, we also conducted subgroup analysis.ResultsIpilimumab plus anti-PD-1 provided an improvement of 1.39 QALYs and 2.48 LYs, at a ICER of $73,163 per QALY. The HR of OS was the variable that had the greatest impact on ICER. Compared to ipilimumab, the probability of ipilimumab plus anti-PD-1 being cost-effective was 94% at the WTP of $150,000/QALY. The results of the subgroup analysis showed that the ICER in the majority of the subgroups was less than $150,000/QALY.ConclusionsIpilimumab plus anti-PD-1 was likely to be cost-effective compared to ipilimumab for patients with metastatic melanoma who are resistant to anti-PD-(L)1 at a WTP threshold of 150,000/QALY.
format	article
author	Ye Peng Xiaohui Zeng Liubao Peng Qiao Liu Lidan Yi Xia Luo Sini Li Liting Wang Shuxia Qin Xiaomin Wan Chongqing Tan
author_facet	Ye Peng Xiaohui Zeng Liubao Peng Qiao Liu Lidan Yi Xia Luo Sini Li Liting Wang Shuxia Qin Xiaomin Wan Chongqing Tan
author_sort	Ye Peng
title	Cost-Effectiveness of Ipilimumab Plus Anti-PD-1 Therapy Versus Ipilimumab Alone in Patients With Metastatic Melanoma Resistant to Anti-PD-(L)1 Monotherapy
title_short	Cost-Effectiveness of Ipilimumab Plus Anti-PD-1 Therapy Versus Ipilimumab Alone in Patients With Metastatic Melanoma Resistant to Anti-PD-(L)1 Monotherapy
title_full	Cost-Effectiveness of Ipilimumab Plus Anti-PD-1 Therapy Versus Ipilimumab Alone in Patients With Metastatic Melanoma Resistant to Anti-PD-(L)1 Monotherapy
title_fullStr	Cost-Effectiveness of Ipilimumab Plus Anti-PD-1 Therapy Versus Ipilimumab Alone in Patients With Metastatic Melanoma Resistant to Anti-PD-(L)1 Monotherapy
title_full_unstemmed	Cost-Effectiveness of Ipilimumab Plus Anti-PD-1 Therapy Versus Ipilimumab Alone in Patients With Metastatic Melanoma Resistant to Anti-PD-(L)1 Monotherapy
title_sort	cost-effectiveness of ipilimumab plus anti-pd-1 therapy versus ipilimumab alone in patients with metastatic melanoma resistant to anti-pd-(l)1 monotherapy
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/a2d7426549cb4e0a9fd8038f8f4f447a
work_keys_str_mv	AT yepeng costeffectivenessofipilimumabplusantipd1therapyversusipilimumabaloneinpatientswithmetastaticmelanomaresistanttoantipdl1monotherapy AT xiaohuizeng costeffectivenessofipilimumabplusantipd1therapyversusipilimumabaloneinpatientswithmetastaticmelanomaresistanttoantipdl1monotherapy AT liubaopeng costeffectivenessofipilimumabplusantipd1therapyversusipilimumabaloneinpatientswithmetastaticmelanomaresistanttoantipdl1monotherapy AT qiaoliu costeffectivenessofipilimumabplusantipd1therapyversusipilimumabaloneinpatientswithmetastaticmelanomaresistanttoantipdl1monotherapy AT lidanyi costeffectivenessofipilimumabplusantipd1therapyversusipilimumabaloneinpatientswithmetastaticmelanomaresistanttoantipdl1monotherapy AT xialuo costeffectivenessofipilimumabplusantipd1therapyversusipilimumabaloneinpatientswithmetastaticmelanomaresistanttoantipdl1monotherapy AT sinili costeffectivenessofipilimumabplusantipd1therapyversusipilimumabaloneinpatientswithmetastaticmelanomaresistanttoantipdl1monotherapy AT litingwang costeffectivenessofipilimumabplusantipd1therapyversusipilimumabaloneinpatientswithmetastaticmelanomaresistanttoantipdl1monotherapy AT shuxiaqin costeffectivenessofipilimumabplusantipd1therapyversusipilimumabaloneinpatientswithmetastaticmelanomaresistanttoantipdl1monotherapy AT xiaominwan costeffectivenessofipilimumabplusantipd1therapyversusipilimumabaloneinpatientswithmetastaticmelanomaresistanttoantipdl1monotherapy AT chongqingtan costeffectivenessofipilimumabplusantipd1therapyversusipilimumabaloneinpatientswithmetastaticmelanomaresistanttoantipdl1monotherapy
_version_	1718441321663823872

Cost-Effectiveness of Ipilimumab Plus Anti-PD-1 Therapy Versus Ipilimumab Alone in Patients With Metastatic Melanoma Resistant to Anti-PD-(L)1 Monotherapy

Ejemplares similares